Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.
2024年6月17日，以色列霍隆，纳斯达克（Nasdaq: CGEN）（TASE: CGEN）生物公司Compugen（复查源）是一家临床阶段的癌症免疫疗法公司，并是计算目标发现的先驱，在2024年6月20日至21日举行的抗体工业研讨会上，该公司的高级副总裁Pierre Ferre博士将介绍有关TIGIT单克隆和双克隆抗体的临床剂量选择的案例研究。地点在法国蒙彼利埃。
Event: 12th Antibody Industrial Symposium, Montpellier, France
Date: Friday, June 21, 2024
Presenter: Pierre Ferré, Ph.D., SVP, Preclinical Development and Corporate Operations, Compugen
Presentation title: Case study on clinical dose selection for TIGIT monospecific and bispecific antibodies
活动：12th抗体工业研讨会，法国蒙彼利埃
日期：2024年6月21日星期五
报告人：Compugen的预临床开发和企业运营高级副总裁Pierre Ferre博士
演讲题目关于TIGIT单克隆和双克隆抗体的临床剂量选择案例研究
About Compugen
关于Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, in IND enabling studies is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Compugen是一家临床阶段的治疗性发现和开发公司，利用其广泛适用的预测性计算发现能力，鉴定新的药物靶点和生物学途径，用于开发癌症免疫治疗。Compugen已开发出两个专有药物候选：COM701，一种潜在的第一类抗-PVRIG抗体和COM902，一种潜在的最佳抗-TIGIT抗体，用于实体肿瘤的治疗。rilvegostomig是一种PD-1/TIGIT双特异性抗体，其TIGIT成分来自Compugen的临床阶段抗TIGIT抗体COM902，在通过许可协议开发双特异性和多特异性抗体方面由阿斯利康开发第3期。此外，公司的早期阶段的免疫肿瘤学疗法管道包括针对各种免疫耐受机制的治疗方案，其中最先进的疗法是授权给吉利德的COM503。COM503是一种潜在的第一类高亲和力抗体，可阻断IL-18结合蛋白和IL-18之间的相互作用，从而在肿瘤微环境中释放天然IL-18以抑制肿瘤生长。Compugen总部位于以色列，旧金山，加州，其他办事处。Compugen的股票在NASDAQ和Tel Aviv Stock Exchange上挂牌，股票代码为CGEN。
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: [email protected]
Tel: +1 (628) 241-0071
公司联系方式：
Yvonne Naughton博士
投资者关系和企业沟通主管
电子邮件：[email protected]
电话：+1 (628) 241-0071
SOURCE Compugen Ltd.
消息来源：Compugen Ltd.